Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tamoxifen and hypercalcaemia

G Daugaard1

  • 1Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.

Acta oncologica (Stockholm, Sweden)·2023
Same author

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Testicular cancer survivors have shorter anogenital distance that is not increased by 1 year of testosterone replacement therapy.

Human reproduction (Oxford, England)·2021
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Close monitoring of serum calcium is crucial when starting tamoxifen therapy, particularly for patients with bone metastases. Hypercalcemia can cause central nervous system symptoms and requires prompt management with hydration and bisphosphonates.

Area of Science:

  • Oncology
  • Endocrinology
  • Medical Case Study

Background:

  • Tamoxifen is a common endocrine therapy for breast cancer.
  • Patients with osseous metastases are at higher risk for certain complications.
  • Central nervous system (CNS) symptoms can arise from various causes during cancer treatment.

Observation:

  • A patient undergoing tamoxifen therapy developed CNS symptoms.
  • Serum calcium levels were elevated, indicating hypercalcemia.
  • The patient had pre-existing bone metastases.

Findings:

  • Hypercalcemia should be considered in patients on endocrine therapy presenting with CNS symptoms.
  • Prompt management of hypercalcemia is essential.
  • Saline hydration is the initial treatment, followed by bisphosphonates for severe cases (serum calcium > 3.50 mmol/l).

Related Experiment Videos

Implications:

  • Highlights the importance of vigilant serum calcium monitoring during tamoxifen initiation in at-risk patients.
  • Emphasizes considering hypercalcemia as a differential diagnosis for CNS changes in patients on endocrine treatment.
  • Informs clinical practice regarding the timely and appropriate management of tamoxifen-induced hypercalcemia.